PT  - JOURNAL ARTICLE
AU  - OTANI, YUSUKE
AU  - MAEKAWA, MASAKI
AU  - TANAKA, ATSUSHI
AU  - PEÑA, TIRSO
AU  - CHIN, VANESSA D.
AU  - ROGACHEVSKAYA, ANNA
AU  - TOYOOKA, SHINICHI
AU  - ROEHRL, MICHAEL H.
AU  - FUJIMURA, ATSUSHI
TI  - C1orf50 Drives Malignant Melanoma Progression Through the Regulation of Stemness
AID  - 10.21873/cgp.20518
DP  - 2025 Jul 01
TA  - Cancer Genomics - Proteomics
PG  - 510--524
VI  - 22
IP  - 4
4099  - http://cgp.iiarjournals.org/content/22/4/510.short
4100  - http://cgp.iiarjournals.org/content/22/4/510.full
SO  - Cancer Genomics Proteomics2025 Jul 01; 22
AB  - Background/Aim: Recent advancements in omics analysis have significantly enhanced our understanding of the molecular pathology of malignant melanoma, leading to the development of novel therapeutic strategies that target specific vulnerabilities within the disease. Despite these improvements, the factors contributing to the poor prognosis of patients with malignant melanoma remain incompletely understood. The aim of this study was to investigate the role of C1orf50 (Chromosome 1 open reading frame 50), a gene previously of unknown function, as a prognostic biomarker in melanoma.Materials and Methods: We performed comprehensive transcriptome data analysis and subsequent functional validation of the human Skin Cutaneous Melanoma project from The Cancer Genome Atlas (TCGA).Results: Elevated expression levels of C1orf50 correlated with worse survival outcomes. Mechanistically, we revealed that C1orf50 plays a significant role in the regulation of cell cycle processes and cancer cell stemness, providing a potential avenue for novel therapeutic interventions in melanoma.Conclusion: This study is the first to identify C1orf50 as a prognostic biomarker in melanoma. The clinical relevance of our results sheds light on the importance of further investigation into the biological mechanisms underpinning C1orf50’s impact on melanoma progression and patient prognosis.